ImpediMed

ImpediMed Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of ImpediMed (IPD.AX) as of Oct 30, 2026 is 10.62. In the previous year, Cash Conversion Cycle (CCC) was 28.42 — a change of -62.64% (lower).

Cash Conversion Cycle

10.62

YoY

-62.64%

Last updated:

Cash Conversion Cycle (CCC) of ImpediMed is 2026 10.62 . Cash Conversion Cycle (CCC) of ImpediMed was 2025 28.42 . It decreases by -62.64% lower compared to the previous year.

The ImpediMed Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
-171.99 AUD
Jan 1, 2020
84.73 AUD
Jan 1, 2021
104.09 AUD
Jan 1, 2022
68.80 AUD
Jan 1, 2023
76.50 AUD
Jan 1, 2024
-16.01 AUD
Jan 1, 2025
28.42 AUD
Jan 1, 2026
10.62 AUD
The ImpediMed Cash Conversion Cycle history
YEARCash Conversion CycleYoY
10.62-62.64%
28.42-277.58%
-16.01-120.92%
76.50+11.20%
68.80-33.90%
104.09+22.84%
84.73-149.27%
-171.99-244.04%
119.40-235.25%
-88.28+98.33%
-44.51-123.88%
186.41-45.25%
340.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Cash Conversion Cycle (CCC) of ImpediMed is 10.62 in 2026.

Cash Conversion Cycle (CCC) of ImpediMed changed from 28.42 to 10.62, representing a -62.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) ImpediMed since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s ImpediMed with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ImpediMed

All Key Metrics — ImpediMed